SABIO-GROUP
15.3.2021 10:02:05 CET | Business Wire | Press release
Sabio Group , Europe’s leading technology and digital CX service provider, has acquired Fonetic , a leading Spanish provider of cloud-enabled AI voicebots, chatbots and customer behaviour analytics solutions. The announcement strengthens Sabio’s AI and Automation solutions offering, enabling the company’s goal of supporting customers with its own truly innovative range of CX solutions to complement its broad multi-vendor product portfolio.
Since its formation in 2006, Fonetic has established itself as a specialist in the provision of voice recognition, Natural Language Processing (NLP) and Artificial Intelligence-powered voicebot and chatbot solutions. Fonetic solutions help organisations to digitally transform their CX operations. The company currently manages, processes and monitors over 200 million interactions per year for major clients including Generali, Axa, Banco Santander, Endesa, , Linea Directa, Mapfre, Multiasistencia and Vodafone.
“We’re now at the stage where it’s reasonable to expect that almost every customer interaction will soon be fronted by AI in some shape or form, and that AI-enabled capabilities are poised to transform customer experience,” explained Sabio’s CEO Jonathan Gale. “With its proven voicebot, chatbot, customer behaviour analytics and visualisation capabilities, Fonetic directly addresses this challenge. The company not only brings an incredibly talented team but valuable expertise in CX digital transactions that will be an important addition to Sabio’s own IP portfolio.”
“At Fonetic we can demonstrate how our voicebots and chatbots perform at scale. This helps our clients to digitally transform their customer engagement by increasing CX efficiencies while also securing significant increases in customer satisfaction,” added Juan Manuel Soto, Fonetic’s CEO and Founder. “As part of the Sabio Group we can bring our voicebot and chatbot offering to a much broader market, especially as AI and automation adoption within the CX sector is set to accelerate exponentially.”
Fonetic works closely with Generali Spain’s Digital Transformation team, and designed and developed the multichannel Bot for Generali in Spain. Commenting, Generali Spain’s Head of Business Transformation and Control, Enrique Lorente said: “Fonetic’s Bot expertise and design skills are a key factor behind the success of our cognitive Bot - by providing a conversational assistant to our distributors and customers, offering automatic claim management, one of Generali’s key and highly volume processes, and allowing them to use the channel of their choice, in an easy and natural way. We look forward to being part of their continued success.”
Fonetic voicebots and chatbots are bot-agnostic and can be deployed using either the company’s own technology or integrated with third-party NLP assets to get the most out of tools such as Microsoft Bot Framework & Luis, Google Dialogflow, IBM Watson, Nuance’s Nina, Sabio’s own solution flexAnswer, Genesys or home assistants like Alexa and Google Home.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005045/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom